Virtual Library

Start Your Search

Victoria Imaz-Olguín

Author of

  • +

    P3.13 - Targeted Therapy (Not CME Accredited Session) (ID 979)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.13-20 - Frequency of EGFR Mutations in Patients with Adenocarcinoma Lung Cancer. Comparative Study Between Public and Private Mexican Health Services (ID 13965)

      12:00 - 13:30  |  Author(s): Victoria Imaz-Olguín

      • Abstract
      • Slides


      The frequency of the EGFR mutation in pulmonary adenocarcinoma varies between 15-40% depending of population reported. Study descriptive, observational, retrospective and multicentric was conducted to determine the frequency of this mutation in public and private centers service in Mexico

      a9ded1e5ce5d75814730bb4caaf49419 Method

      They were selected patients with diagnosed of pulmonary adenocarcinoma between January 2011 and January 2016 from three oncology centers, two private centers (ABC Medical Center and the Spanish Hospital) and one public (National Institute of Respiratory Diseases). The total sample was 328 patients, subdivided by the presence or not of EGFR mutations. The primary objective was the mutation in EGFR and the secondary the type of mutation, frequency by sex, type of treatment and clinical stage at the time of diagnosis.

      4c3880bb027f159e801041b1021e88e8 Result

      The sample was formed by 136 (41%) men and 195 (59%) women, the average age of diagnosis was 62.4 years, the clinical stage in 75.7% was IV at the time of diagnosis. The total frequency of the EGFR mutation was 42.7% (140 patients), the most prevalent being Del19 (66.4%) and L858R (30%). These mutations were present in 113 patients of INER (34.5%) and by both private centers was 27 patients (8.2%), this difference was significant when comparing hospital types (public vs. private, p 0.033). Men showed a protective factor for the EGFR mutation compared to women with HR 0.88 (p 0.028), there were differences between the possibility of presenting the EGFR mutation in patients with lung cancer, with less possibility of presenting it if medical attention was done in a private medium compared to the public medium with a HR 0.81 (p .001).

      8eea62084ca7e541d918e823422bd82e Conclusion

      There is a significant difference in the frequency of mutations in EGFR between the public and private hospital, probably associated with ethnic, genetic, environmental and social differences between the two populations.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.